Cover Image

Real‐world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL‐CLLEAR study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Anna Panovská, Pavel Žák, Tereza Jurková, Tomáš Arpáš, Yvona Brychtová, Alžběta Vašíková, Viera Hrabčáková, Adéla Prchlíková, Martina Filipová, Michael Doubek
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Hematological Oncology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

553 | DIGITAL TECHNOLOGY AND NATURAL LANGUAGE PROCESSING IN ACTION: EXPLORING THE BELGIAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT POPULATION WITH THE BE‐CLLEAR STUDY
by: M. Vanderkerken, et al.
Published: (2025)

Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax
by: Stefano Cordella, et al.
Published: (2024)

Clonal dynamics of Richter transformation in chronic lymphocytic leukemia
by: Hanyin Wang, et al.
Published: (2024)

The RAS‐signaling‐pathway‐mutation‐related prognosis in B‐cell acute lymphoblastic leukemia: A report from South China children's leukemia group
by: Xinyu Li, et al.
Published: (2024)

FLT3‐ITD regulation of the endoplasmic reticulum functions in acute myeloid leukemia
by: María Turos‐Cabal, et al.
Published: (2024)

Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications
by: N. Polverelli, et al.
Published: (2024)

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia
by: Jana Gregorova, et al.
Published: (2025)

Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect
by: Jinrong Yang, et al.
Published: (2024)

Research on the mechanism of HOPX‐HDAC2 interaction inducing differentiation blockage in acute myeloid leukemia
by: Fang He, et al.
Published: (2024)

Treatment‐free remission as a new goal in the management of chronic myeloid leukemia: Clinical and biological aspects
by: Daniele Cattaneo, et al.
Published: (2024)

How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia
by: Nayla Mouawad, et al.
Published: (2024)

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia
by: Sudhir Manda, et al.
Published: (2024)

Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia
by: Yuan Sun, et al.
Published: (2024)

Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis
by: Rong Wang, et al.
Published: (2024)

ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B‐cell acute lymphoblastic leukemia
by: Zong‐Yan Shi, et al.
Published: (2024)

Characteristics, outcomes and health care utilization of patients with acute myeloid leukemia aged 70 years or older: A single‐center retrospective analysis
by: Marie Anne‐Catherine Neumann, et al.
Published: (2024)

Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt‐related transcription factor 1 mutation: A single‐center retrospective analysis
by: Lin‐Ya Wang, et al.
Published: (2024)

504 | IMPACT OF THE NEUTROPHIL/LYMPHOCYTE RATIO ON OUTCOMES FOLLOWING BISPECIFIC ANTIBODY THERAPY IN RELAPSED/REFRACTORY LYMPHOMA PATIENTS
by: A. M. Bock, et al.
Published: (2025)

Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus‐based position paper from an ad hoc expert panel
by: Francesca Romana Mauro, et al.
Published: (2024)

Treatment‐related toxicity disparities in adult Hispanic acute lymphoblastic leukemia patients receiving pegaspargase‐based regimens: A multicenter electronic health research network study
by: Benjamin J. Lee, et al.
Published: (2024)

Allogeneic transplantation for adult T‐cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy
by: Hidehiro Itonaga, et al.
Published: (2024)

214 | FINAL INDEPENDENT REVIEW DATA SUPPORTS SUSTAINED BENEFIT OF ZANUBRUTINIB OVER IBRUTINIB IN PATIENTS WITH R/R CLL/SLL IN ALPINE
by: J. R. Brown, et al.
Published: (2025)

Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis
by: Mariarita Sciumè, et al.
Published: (2024)

Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting
by: Taku Kikuchi, et al.
Published: (2024)

OT02 | CLL18/MOIRAI TRIAL AIMING TO ESTABLISH MEASUREMENT OF INDIVIDUAL RESIDUAL DISEASE FOR ADJUSTMENT OF TREATMENT DURATION TO IMPROVE OUTCOMES IN TREATMENT‐NAIVE CLL/SLL
by: P. Cramer, et al.
Published: (2025)

Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
by: James R. Cerhan, et al.
Published: (2025)

Optimizing Fixed‐Duration Ven‐I Regimen in CLL: Expert Insight and AI Comparison
by: V. Innao, et al.
Published: (2026)

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
by: Ernesto Vigna, et al.
Published: (2025)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
by: Juliette Penichoux, et al.
Published: (2025)

Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis
by: Maria Livia Del Giudice, et al.
Published: (2024)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
by: Tengfei Shi, et al.
Published: (2025)

Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
by: Akihiko Izumi, et al.
Published: (2025)

Identifying Clones in Myelodysplastic Syndromes by Using Single‐Cell RNA Sequencing
by: Roy Pollak, et al.
Published: (2026)

444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
by: V. Musteata, et al.
Published: (2025)

72 | SEQUOIA 5‐YEAR FOLLOW‐UP IN ARM C: FRONTLINE ZANUBRUTINIB IN PATIENTS WITH DEL(17P) AND TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
by: C. S. Tam, et al.
Published: (2025)

In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T‐Cell Neoplasms
by: Marie Therese Manipadam, et al.
Published: (2024)

Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
by: Fuli Fan, et al.
Published: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
by: Yutaka Shimazu, et al.
Published: (2025)

598 | REDEFINING CLASSIFICATION ALGORITHM AND STAGING SYSTEM IN MARGINAL ZONE LYMPHOMA
by: C. Bommier, et al.
Published: (2025)

Clinical Outcome of Extramedullary Multiple Myeloma in the Era of Novel Agents: Insights From a Multicenter Study
by: Dong Liang, et al.
Published: (2025)